Outpatient management of the chronically anticoagulated patient for elective surgery

Anaesthesia and Intensive Care

Volumn 31, Issue 2, 2003, Pages 145-154

  Watts, S A ^a   Gibbs, N M ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Anaesthesia, surgery: anticoagulation, perioperative planning, outpatient management, warfarin, low molecular weight heparin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOCAL ANESTHETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; WARFARIN;

AMBULATORY CARE; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTIVE SURGERY; EMBOLISM; EPIDURAL HEMATOMA; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; MAJOR SURGERY; MINOR SURGERY; OPTIMAL DRUG DOSE; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; RECURRENCE RISK; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0037397501     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0303100202     Document Type: Review

References (48)

1. Albers G. Atrial fibrillation and stroke. Arch Intern Med 1994; 154:1443-1448.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154:1449-1457.
3. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: Echocardiographic features of patients at risk. Ann Intern Med 1992; 116:6-12.
4. Koefoed B, Gullov A, Peterson P. Prevention of thromboembolic events in atrial fibrillation. Thromb Haemost 1997; 78:377-381.
5. Vongpatanasin W, Hills D, Lange RA. Prosthetic heart valves. N Engl J Med 1995; 335:407-415.
6. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St Jude medical prostheses. J Heart Valve Dis 1993; 2:291-301.
7. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses (Review). Circulation 1994; 89:635-641.
8. Feng F, Busuttil R. Carotid surgery in stroke prevention. Amer Fam Physician 1986; 33:109-124.
9. Sherman D,Dyken M, Gent M, Harrrison M, Hart R, Mohr J. Antithrombotic therapy for cerebrovascular disorders. Chest 1995; 108 (Suppl):444S-457S.
10. Goldstein L, Bonito A, Matchar D, Duncan P, Samsa G. US national survery of physician practices for the secondary and tertiary prevention of ischaemic stroke. Stroke 1996; 27:1473-1478.
11. Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomised controlled trial of carotid endarterecomy for asymptomatic carotid stenosis. Mayo Clin Proc 1992; 67:597-600.
12. Lindblad B, Persson N, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993; 24:1125-1258..
13. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 223:1506-1511.
14. Palmer A, Schramm W, Kirchhof B, Bergemann R. Low molecular weight heparin for prevention of thrombo-embolism in general surgery: A meta-analysis of randomised clinical trials. Haemostasis 1997; 27:65-74.
15. Koch A, Bouges S, Zeigler H, Dinkel J, Daures P, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analysis. Br J Surg 1997; 84:750-759.
16. Nurmohamed M, Verhaeghe R, Haas S et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep venous thrombosis in general surgery. Am J Surg 1995; 169:567-571.
17. Spandorfer J, Lynch S, Weitz H, Fertel S, Merli G. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84:478-480.
18. Verhaeghe R. The use of low-molecular-weight heparins in cardiovascular disease. Acta Cardiol 1998; 53:15-21.
19. Horlocker T, Heit J. Low molecular weight heparins: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg 1997; 85:874-885.
20. Meyer G, Brenot F, Pacouret G et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non-massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995; 74:1432-1435.
21. Hallert C, Blomqvist K. Simplified ambulatory treatment of thrombosis. A daily dosage of subcutaneous low-molecular-weight heparin. Lakartidningen 1995; 92:3011-3013.
22. Lindmarker P, Holstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility study in an outpatient setting. J Intern Med 1996; 240:395-401.
23. Ting S, Ziegenbcin R, Gan TE et al. Dalteparin for deep venous thrombosis: a hospital-in-the-home program. Med J Aust 1998; 168:272-276.
24. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64:506-510.
25. Harenberg J, Huhle G, Piazolo L, Giese C, Heene D. Longterm anticoagulation of outpatients with adverse events to oral anticoagutants using low-molecular-weight heparin. Semin Thromb Hemost 1997; 23:167-172.
26. Hirsh J. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemostasis 1996; (Suppl 4):189-198.
27. Harenberg J, Weuster B, Pfitzer M et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost 1993;19 (Suppl 1): 116-121.
28. Samama C, Combe S, III P, Barre E, Dreux S, Viars P. Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi? Haemostasis 1996; 26 (Suppl 2): 57-64.
29. Harenberg J, Leber G, Dempfle C, Heene D, Zimmermann R, Kubler W. Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulation. Nouv Rev Fr Hematol 1989; 31:363-369.
30. Cohen M, Demers C, Gurfunkel E et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447-452.
31. Klein W, Buchwald A, Hillis S et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation 1997; 96:61-68.
32. Nurmohamed M, ten Cate H, ten Cate J. Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations. Drugs 1997; 53:736-751.
33. Berdauge P, Boneu B, Soula P, Dambrin C, Vernhet J, Cerene A. Usefulness of low-molecular-weight heparins during postoperative period in mitral mechanical valve replacement: clinical ischaemic and haemorrhagic complications in 110 cases. Eur Heart J 1998; 19 (Suppl):534-539.
34. Eriksson B, Soderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73:398-401.
35. Horlocker TT, Wedel DJ. Anticoagulation and neuroaxial block: Historical perspective, anesthetic implications, and risk management. Reg Anesth Pain Med 1998; 23 (Suppl):129-134.
36. Horlocker TT, Wedel D. Neuraxial block and low molecular weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23 (Suppl): 164-177.
37. Shalaby A, Mohiuddin S. Anticoagulation and elective surgery. N Engl J Med 1997; 337:939.
38. Spandorfer J, Merli G. Anticoagulation and surgery. N Engl J Med 1997; 337:938.
39. Lowson S, Hanson E. Anticoagulation and surgery. N Engl J Med 1997; 337:938.
40. Sridhar R, Grigg A. The perioperative management of anticoagulation. Aust Prescr 2000;23:13-16.
41. Otley C, Fewkes J, Frank W, Olbricht S. Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Arch Dermatol 1996; 132:161-166.
42. Devani P Lavery K, Howell C. Dental extractions in patients on warfarin: is alteration of anticoagulant regime necessary? Br J Oral Maxillofac Surg 1998; 36:107-111.
43. Kingston T, Nonnenmacher A, Crowe H, Costello A, Street A. Further evaluation of transurethral laser ablation of the prostate in patients treated with anticoagulant therapy. Aust NZ J Surg 1995; 65:40-43.
44. Kearon C. Perioperative management of long-term anticoagulation. Semin Thromb Hemost 1998; 24 (Suppl 1):77-83.
45. Enneking FK, Benzon H. Oral anticoagulants and regional anesthesia: a perspective. Reg Anesth Pain Med 1998; 23 (Suppl):140-145.
46. Liu S, Mulroy M. Neuraxial anesthesia in the presence of standard heparin. Reg Anesth Pain Med. 1998; 23 (Suppl): 157-163.
47. Urmey W, Rowlingson J. Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Reg Anesth Pain Med 1998; 23 (Suppl):146-151.
48. Horlocker T, Wedel D. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic. Anesth Analg 1998; 86:1153-1156.